The importance of KRAS status in managing metastatic colorectal cancer

Stephen Leong, S. Gai Eckhardt, Antonio Jimeno, Wells Messersmith

Research output: Contribution to journalReview article

Abstract

In the past decade, the standard of care for advanced colorectal cancer has been in a state of flux with the introduction of new agents in the treatment of stage IV disease; however, the 5-year survival rate for advanced disease remains low. Investigators are trying to identify biomarkers that may be predictive and/or prognostic for these agents and thereby improve patient outcomes. This article discusses recent discoveries that have identified the importance of KRAS mutational status in predicting responses to epidermal growth factor receptor-targeting antibodies (cetuximab and panitumumab) in the management of metastatic colon cancer.

Original languageEnglish (US)
Pages (from-to)129-134
Number of pages6
JournalCurrent Colorectal Cancer Reports
Volume5
Issue number3
DOIs
StatePublished - Jul 1 2009

Fingerprint

Colorectal Neoplasms
Standard of Care
Epidermal Growth Factor Receptor
Colonic Neoplasms
Survival Rate
Biomarkers
Research Personnel
Antibodies
Therapeutics
panitumumab
Cetuximab

ASJC Scopus subject areas

  • Hepatology
  • Oncology
  • Gastroenterology

Cite this

The importance of KRAS status in managing metastatic colorectal cancer. / Leong, Stephen; Eckhardt, S. Gai; Jimeno, Antonio; Messersmith, Wells.

In: Current Colorectal Cancer Reports, Vol. 5, No. 3, 01.07.2009, p. 129-134.

Research output: Contribution to journalReview article

Leong, Stephen ; Eckhardt, S. Gai ; Jimeno, Antonio ; Messersmith, Wells. / The importance of KRAS status in managing metastatic colorectal cancer. In: Current Colorectal Cancer Reports. 2009 ; Vol. 5, No. 3. pp. 129-134.
@article{03477768243243a78951877f04e00a1b,
title = "The importance of KRAS status in managing metastatic colorectal cancer",
abstract = "In the past decade, the standard of care for advanced colorectal cancer has been in a state of flux with the introduction of new agents in the treatment of stage IV disease; however, the 5-year survival rate for advanced disease remains low. Investigators are trying to identify biomarkers that may be predictive and/or prognostic for these agents and thereby improve patient outcomes. This article discusses recent discoveries that have identified the importance of KRAS mutational status in predicting responses to epidermal growth factor receptor-targeting antibodies (cetuximab and panitumumab) in the management of metastatic colon cancer.",
author = "Stephen Leong and Eckhardt, {S. Gai} and Antonio Jimeno and Wells Messersmith",
year = "2009",
month = "7",
day = "1",
doi = "10.1007/s11888-009-0019-4",
language = "English (US)",
volume = "5",
pages = "129--134",
journal = "Current Colorectal Cancer Reports",
issn = "1556-3790",
publisher = "Springer Science + Business Media",
number = "3",

}

TY - JOUR

T1 - The importance of KRAS status in managing metastatic colorectal cancer

AU - Leong, Stephen

AU - Eckhardt, S. Gai

AU - Jimeno, Antonio

AU - Messersmith, Wells

PY - 2009/7/1

Y1 - 2009/7/1

N2 - In the past decade, the standard of care for advanced colorectal cancer has been in a state of flux with the introduction of new agents in the treatment of stage IV disease; however, the 5-year survival rate for advanced disease remains low. Investigators are trying to identify biomarkers that may be predictive and/or prognostic for these agents and thereby improve patient outcomes. This article discusses recent discoveries that have identified the importance of KRAS mutational status in predicting responses to epidermal growth factor receptor-targeting antibodies (cetuximab and panitumumab) in the management of metastatic colon cancer.

AB - In the past decade, the standard of care for advanced colorectal cancer has been in a state of flux with the introduction of new agents in the treatment of stage IV disease; however, the 5-year survival rate for advanced disease remains low. Investigators are trying to identify biomarkers that may be predictive and/or prognostic for these agents and thereby improve patient outcomes. This article discusses recent discoveries that have identified the importance of KRAS mutational status in predicting responses to epidermal growth factor receptor-targeting antibodies (cetuximab and panitumumab) in the management of metastatic colon cancer.

UR - http://www.scopus.com/inward/record.url?scp=79952641879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952641879&partnerID=8YFLogxK

U2 - 10.1007/s11888-009-0019-4

DO - 10.1007/s11888-009-0019-4

M3 - Review article

AN - SCOPUS:79952641879

VL - 5

SP - 129

EP - 134

JO - Current Colorectal Cancer Reports

JF - Current Colorectal Cancer Reports

SN - 1556-3790

IS - 3

ER -